Cargando…
Evaluation of novel oral vaccine candidates and validation of a caprine model of Johne's disease
Johne's disease (JD) caused by Mycobacterium avium subspecies paratuberculosis (MAP) is a major threat to the dairy industry and possibly some cases of Crohn's disease in humans. A MAP vaccine that reduced of clinical disease and/or reduced fecal shedding would aid in the control of JD. Th...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3941644/ https://www.ncbi.nlm.nih.gov/pubmed/24624365 http://dx.doi.org/10.3389/fcimb.2014.00026 |
_version_ | 1782305957164875776 |
---|---|
author | Hines, Murray E. Turnquist, Sue E. Ilha, Marcia R. S. Rajeev, Sreekumari Jones, Arthur L. Whittington, Lisa Bannantine, John P. Barletta, Raúl G. Gröhn, Yrjö T. Katani, Robab Talaat, Adel M. Li, Lingling Kapur, Vivek |
author_facet | Hines, Murray E. Turnquist, Sue E. Ilha, Marcia R. S. Rajeev, Sreekumari Jones, Arthur L. Whittington, Lisa Bannantine, John P. Barletta, Raúl G. Gröhn, Yrjö T. Katani, Robab Talaat, Adel M. Li, Lingling Kapur, Vivek |
author_sort | Hines, Murray E. |
collection | PubMed |
description | Johne's disease (JD) caused by Mycobacterium avium subspecies paratuberculosis (MAP) is a major threat to the dairy industry and possibly some cases of Crohn's disease in humans. A MAP vaccine that reduced of clinical disease and/or reduced fecal shedding would aid in the control of JD. The objectives of this study were (1) to evaluate the efficacy of 5 attenuated strains of MAP as vaccine candidates compared to a commercial control vaccine using the protocol proposed by the Johne's Disease Integrated Program (JDIP) Animal Model Standardization Committee (AMSC), and (2) to validate the AMSC Johne's disease goat challenge model. Eighty goat kids were vaccinated orally twice at 8 and 10 weeks of age with an experimental vaccine or once subcutaneously at 8 weeks with Silirum® (Zoetis), or a sham control oral vaccine at 8 and 10 weeks. Kids were challenged orally with a total of approximately 1.44 × 10(9) CFU divided in two consecutive daily doses using MAP ATCC-700535 (K10-like bovine isolate). All kids were necropsied at 13 months post-challenge. Results indicated that the AMSC goat challenge model is a highly efficient and valid model for JD challenge studies. None of the experimental or control vaccines evaluated prevented MAP infection or eliminated fecal shedding, although the 329 vaccine lowered the incidence of infection, fecal shedding, tissue colonization and reduced lesion scores, but less than the control vaccine. Based on our results the relative performance ranking of the experimental live-attenuated vaccines evaluated, the 329 vaccine was the best performer, followed by the 318 vaccine, then 316 vaccine, 315 vaccine and finally the 319 vaccine was the worst performer. The subcutaneously injected control vaccine outperformed the orally-delivered mutant vaccine candidates. Two vaccines (329 and 318) do reduce presence of JD gross and microscopic lesions, slow progression of disease, and one vaccine (329) reduced fecal shedding and tissue colonization. |
format | Online Article Text |
id | pubmed-3941644 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-39416442014-03-12 Evaluation of novel oral vaccine candidates and validation of a caprine model of Johne's disease Hines, Murray E. Turnquist, Sue E. Ilha, Marcia R. S. Rajeev, Sreekumari Jones, Arthur L. Whittington, Lisa Bannantine, John P. Barletta, Raúl G. Gröhn, Yrjö T. Katani, Robab Talaat, Adel M. Li, Lingling Kapur, Vivek Front Cell Infect Microbiol Microbiology Johne's disease (JD) caused by Mycobacterium avium subspecies paratuberculosis (MAP) is a major threat to the dairy industry and possibly some cases of Crohn's disease in humans. A MAP vaccine that reduced of clinical disease and/or reduced fecal shedding would aid in the control of JD. The objectives of this study were (1) to evaluate the efficacy of 5 attenuated strains of MAP as vaccine candidates compared to a commercial control vaccine using the protocol proposed by the Johne's Disease Integrated Program (JDIP) Animal Model Standardization Committee (AMSC), and (2) to validate the AMSC Johne's disease goat challenge model. Eighty goat kids were vaccinated orally twice at 8 and 10 weeks of age with an experimental vaccine or once subcutaneously at 8 weeks with Silirum® (Zoetis), or a sham control oral vaccine at 8 and 10 weeks. Kids were challenged orally with a total of approximately 1.44 × 10(9) CFU divided in two consecutive daily doses using MAP ATCC-700535 (K10-like bovine isolate). All kids were necropsied at 13 months post-challenge. Results indicated that the AMSC goat challenge model is a highly efficient and valid model for JD challenge studies. None of the experimental or control vaccines evaluated prevented MAP infection or eliminated fecal shedding, although the 329 vaccine lowered the incidence of infection, fecal shedding, tissue colonization and reduced lesion scores, but less than the control vaccine. Based on our results the relative performance ranking of the experimental live-attenuated vaccines evaluated, the 329 vaccine was the best performer, followed by the 318 vaccine, then 316 vaccine, 315 vaccine and finally the 319 vaccine was the worst performer. The subcutaneously injected control vaccine outperformed the orally-delivered mutant vaccine candidates. Two vaccines (329 and 318) do reduce presence of JD gross and microscopic lesions, slow progression of disease, and one vaccine (329) reduced fecal shedding and tissue colonization. Frontiers Media S.A. 2014-03-04 /pmc/articles/PMC3941644/ /pubmed/24624365 http://dx.doi.org/10.3389/fcimb.2014.00026 Text en Copyright © 2014 Hines, Turnquist, Ilha, Rajeev, Jones, Whittington, Bannantine, Barletta, Gröhn, Katani, Talaat, Li and Kapur. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Microbiology Hines, Murray E. Turnquist, Sue E. Ilha, Marcia R. S. Rajeev, Sreekumari Jones, Arthur L. Whittington, Lisa Bannantine, John P. Barletta, Raúl G. Gröhn, Yrjö T. Katani, Robab Talaat, Adel M. Li, Lingling Kapur, Vivek Evaluation of novel oral vaccine candidates and validation of a caprine model of Johne's disease |
title | Evaluation of novel oral vaccine candidates and validation of a caprine model of Johne's disease |
title_full | Evaluation of novel oral vaccine candidates and validation of a caprine model of Johne's disease |
title_fullStr | Evaluation of novel oral vaccine candidates and validation of a caprine model of Johne's disease |
title_full_unstemmed | Evaluation of novel oral vaccine candidates and validation of a caprine model of Johne's disease |
title_short | Evaluation of novel oral vaccine candidates and validation of a caprine model of Johne's disease |
title_sort | evaluation of novel oral vaccine candidates and validation of a caprine model of johne's disease |
topic | Microbiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3941644/ https://www.ncbi.nlm.nih.gov/pubmed/24624365 http://dx.doi.org/10.3389/fcimb.2014.00026 |
work_keys_str_mv | AT hinesmurraye evaluationofnoveloralvaccinecandidatesandvalidationofacaprinemodelofjohnesdisease AT turnquistsuee evaluationofnoveloralvaccinecandidatesandvalidationofacaprinemodelofjohnesdisease AT ilhamarciars evaluationofnoveloralvaccinecandidatesandvalidationofacaprinemodelofjohnesdisease AT rajeevsreekumari evaluationofnoveloralvaccinecandidatesandvalidationofacaprinemodelofjohnesdisease AT jonesarthurl evaluationofnoveloralvaccinecandidatesandvalidationofacaprinemodelofjohnesdisease AT whittingtonlisa evaluationofnoveloralvaccinecandidatesandvalidationofacaprinemodelofjohnesdisease AT bannantinejohnp evaluationofnoveloralvaccinecandidatesandvalidationofacaprinemodelofjohnesdisease AT barlettaraulg evaluationofnoveloralvaccinecandidatesandvalidationofacaprinemodelofjohnesdisease AT grohnyrjot evaluationofnoveloralvaccinecandidatesandvalidationofacaprinemodelofjohnesdisease AT katanirobab evaluationofnoveloralvaccinecandidatesandvalidationofacaprinemodelofjohnesdisease AT talaatadelm evaluationofnoveloralvaccinecandidatesandvalidationofacaprinemodelofjohnesdisease AT lilingling evaluationofnoveloralvaccinecandidatesandvalidationofacaprinemodelofjohnesdisease AT kapurvivek evaluationofnoveloralvaccinecandidatesandvalidationofacaprinemodelofjohnesdisease |